|
|
The Body Covers: The 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Conference Summaries: Day Three
Tuesday, December 18, 2001
- Meet the Experts (Session 132)
- HIV Session II (Slide Session 142)
- Viruses, Fungi and Bacterial Pathogenesis (Late-Breaker Slide Session 164b)
- Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptidic Protease Inhibitor, Plus Ritonavir (RTV) in PI-Failure Patients (Abstract LB-15)
Coverage by Andrew T. Pavia, M.D.
- Once-Daily Atazanavir Plus Saquinavir Favorably Affects Total Cholesterol (TC) and Fasting Triglyceride (TG) Profiles in Patients Failing Prior PI Therapy (Trial AI424-009, Week 24) (Abstract LB-16)
Coverage by Brian A. Boyle, M.D., J.D.
- The Prevalence of Antiretroviral Drug Resistance in the U.S. (Abstract LB-17)
Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
- Prognosis of HIV-1 Infected Drug-Naive Patients Starting Potent Antiretroviral Therapy: Multi-Cohort Analysis of 12,040 Patients (Abstract LB-18)
Coverage by Edwin DeJesus, M.D.
- Meet the Experts (Session 170)
- Antiretroviral Agents: Adherence, Pharmacokinetics and Pharmacodynamics (Poster Session 175)
- Antiretroviral Resistance (Poster Session 176)
- Virologic Response to Antiretroviral Therapy in Chronically HIV-1-Infected, Antiretroviral-Naive Adults with Baseline Genotypic Resistance (Abstract 1747)
Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
- Impact of M184V/I Mutation on HIV Phenotypic Resistance to Nucleoside Analogs (NRTIs) in NRTI-Experienced Patients (Abstract 1759)
Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
- Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial (Abstract 1761)
Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
- Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (Abstract 1765)
Coverage by Andrew T. Pavia, M.D.
- Impact on Fitness Conferred by Amprenavir (APV) Resistance Mutations (Abstract 1766)
Coverage by Andrew T. Pavia, M.D.
- Herpes Viruses (Poster Session 192)
- Antiretroviral Therapy I (Poster Session 193)
- Antiretroviral Therapy II (Poster Session 194)
- HIV Pathogenesis and Laboratory Testing (Poster Session 195)
|
Advertisement
|